Literature DB >> 11303589

Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism.

M T Goodman1, K McDuffie, L N Kolonel, K Terada, T A Donlon, L R Wilkens, C Guo, L Le Marchand.   

Abstract

Steroid hormones, such as estrogens, appear to be associated with ovarian carcinogenesis, but the precise biological mechanisms are unclear. Polymorphisms in genes that regulate the concentration of estrogens and their metabolites may contribute directly to the individual variation in ovarian cancer risk through a mechanism involving oxidative stress or indirectly by influencing ovarian cancer susceptibility associated with ovulation and reproduction. We conducted a population-based, case-control study of primary ovarian cancer between 1993 and 1999 in Hawaii to test several genetic and related hypotheses. A personal interview and blood specimen were obtained in the subjects' homes. In a sample of 129 epithelial ovarian cancer cases and 144 controls, we compared the frequencies of several polymorphisms in genes that regulate steroid hormone metabolism and catecholestrogen formation. Multivariate unconditional logistic regression was used to model the association of each genetic polymorphism separately after adjusting for age, ethnicity, and other covariates. The high-activity Val432 allele of the CYP1B1 gene, which may be linked to oxidative stress through elevated 4-hydroxylated catecholestrogen formation, was associated with an increased risk of ovarian cancer. The Val/Leu genotype for CYP1B1 was associated with an odds ratio of 1.8 (95% confidence interval, 1.0-3.3) and the Val/Val genotype with an odds ratio of 3.8 (95% confidence interval, 1.2-11.4) compared with the Leu/Leu genotype (P = 0.005). Tobacco smokers with at least one CYP1A1 (MspI) m2 allele, one CYP1B1 Val allele, one COMT Met allele, or two CYP1A2 A alleles were at significantly increased risk of ovarian cancer compared to never-smokers with CYP1A1 (MspI) ml/ml, CYP1B1 Leu/Leu, COMT Val/Val, or CYP1A2 A/A genotypes, respectively. We found a positive statistical interaction (P = 0.03) between tobacco smoking and the CYP1A1 (MspI) polymorphism on the risk of ovarian cancer. None of the other gene-environment (pregnancy, oral contraceptive pill use) or gene-gene interactions were statistically significant. Although not significant, there was a suggestion that the effect of the CYP1B1 Val allele was reduced substantially in the presence of the high-activity COMT Met allele. These findings suggest that the CYP1B1-Val allele and perhaps other genetic polymorphisms in combination with environmental or hormonal exposures are susceptibility factors for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303589

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Unbalanced estrogen metabolism in ovarian cancer.

Authors:  Muhammad Zahid; Cheryl L Beseler; James B Hall; Tricia LeVan; Ercole L Cavalieri; Eleanor G Rogan
Journal:  Int J Cancer       Date:  2014-01-25       Impact factor: 7.396

Review 2.  Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.

Authors:  Carsten Skarke; Anja Kirchhof; Gerd Geisslinger; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

3.  Association between the CYP1A2 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Wen-Xia Sun; Ying-Hua Chen; Zhi-Zhong Liu; Jian-Jun Xie; Wei Wang; Ya-Ping Du; Yu Chen; Xu-Liang Shen; Xiao-Feng He; Li-Xia Wu; Wu Wei; Lin Zhang
Journal:  Mol Genet Genomics       Date:  2014-12-04       Impact factor: 3.291

4.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jie-Ying Liu; Yu Yang; Zhi-Zhong Liu; Jian-Jun Xie; Ya-Ping Du; Wei Wang
Journal:  Mol Genet Genomics       Date:  2014-12-05       Impact factor: 3.291

5.  Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing.

Authors:  Erin Madeen; Lisbeth K Siddens; Sandra Uesugi; Tammie McQuistan; Richard A Corley; Jordan Smith; Katrina M Waters; Susan C Tilton; Kim A Anderson; Ted Ognibene; Kenneth Turteltaub; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2018-12-21       Impact factor: 4.219

6.  Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis.

Authors:  Theodoros N Sergentanis; Konstantinos P Economopoulos; Souzana Choussein; Nikos F Vlahos
Journal:  Mol Biol Rep       Date:  2012-06-26       Impact factor: 2.316

7.  Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility.

Authors:  Ivana Rizzuto; Renee F Behrens; Lesley A Smith
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

8.  Identification of a novel haplotype of the human catechol-O-methyltransferase gene.

Authors:  Hyoung-Woo Bai; Bao Ting Zhu
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

9.  Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.

Authors:  Marc T Goodman; Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

10.  The ovarian carcinoma risk with the polymorphisms of CYP1B1 come from the positive selection.

Authors:  Liying Zhang; Liyuan Feng; Meng Lou; Xihan Deng; Chuanzhong Liu; Li Li
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.